BR112015030287A2 - ensaios, métodos e kits para analisar a sensibilidade e resistência a fármacos anti-câncer, prevendo o prognóstico de um paciente oncológico e estratégias de tratamento personalizadas - Google Patents

ensaios, métodos e kits para analisar a sensibilidade e resistência a fármacos anti-câncer, prevendo o prognóstico de um paciente oncológico e estratégias de tratamento personalizadas

Info

Publication number
BR112015030287A2
BR112015030287A2 BR112015030287A BR112015030287A BR112015030287A2 BR 112015030287 A2 BR112015030287 A2 BR 112015030287A2 BR 112015030287 A BR112015030287 A BR 112015030287A BR 112015030287 A BR112015030287 A BR 112015030287A BR 112015030287 A2 BR112015030287 A2 BR 112015030287A2
Authority
BR
Brazil
Prior art keywords
individual
methods
kits
cancerous tumor
drugs
Prior art date
Application number
BR112015030287A
Other languages
English (en)
Inventor
A Ince Tan
Original Assignee
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Miami filed Critical Univ Miami
Publication of BR112015030287A2 publication Critical patent/BR112015030287A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

resumo da patente de invenã§ã£o para: “ensaios, mã‰todos e kits para analisar a sensibilidade e resistãšncia a fãrmacos anti-cã‚ncer, prevendo o prognã“stico de um paciente oncolã“gico e estratã‰gias de tratamento personalizadas.” a presente invenã§ã£o descreve ensaios, mã©todos e kits para analisar a sensibilidade de um tumor cancerã­geno de um indivã­duo a um fã¡rmaco, prevendo respostas do tumor cancerã­geno aos fã¡rmacos, determinando o prognã³stico de um indivã­duo tendo um tumor cancerã­geno e desenvolvendo uma terapia personalizada ou estratã©gia de tratamento para o indivã­duo. os ensaios, mã©todos e kits envolvem analisar o perfil ou assinatura da expressã£o gãªnica e proteica do tumor cancerã­geno de um indivã­duo, testando fã¡rmacos candidatos em cã©lulas cancerã­genas provenientes do tumor cancerã­geno do indivã­duo, e classificando o tumor cancerã­geno do indivã­duo com base em assinaturas de expressã£o gãªnica de cã©lula de origem das cã©lulas ovarianas e cã©lulas das trompas de falã³pio. usando estes mã©todos, um fã¡rmaco (ou fã¡rmacos) adequado ã© identificado, o indivã­duo pode ser tratado com esse fã¡rmaco e uma terapia personalizada pode ser desenvolvida para o indivã­duo.
BR112015030287A 2013-06-04 2014-06-04 ensaios, métodos e kits para analisar a sensibilidade e resistência a fármacos anti-câncer, prevendo o prognóstico de um paciente oncológico e estratégias de tratamento personalizadas BR112015030287A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361830709P 2013-06-04 2013-06-04
PCT/US2014/040806 WO2014197543A1 (en) 2013-06-04 2014-06-04 Assays, methods and kits for analyzing sensitivity and resistance to anti-cancer drugs, predicting a cancer patient's prognosis, and personalized treatment strategies

Publications (1)

Publication Number Publication Date
BR112015030287A2 true BR112015030287A2 (pt) 2017-07-25

Family

ID=52008548

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015030287A BR112015030287A2 (pt) 2013-06-04 2014-06-04 ensaios, métodos e kits para analisar a sensibilidade e resistência a fármacos anti-câncer, prevendo o prognóstico de um paciente oncológico e estratégias de tratamento personalizadas

Country Status (7)

Country Link
US (1) US20160102365A1 (pt)
EP (1) EP3004394A4 (pt)
JP (1) JP2016523527A (pt)
AU (1) AU2014275006A1 (pt)
BR (1) BR112015030287A2 (pt)
CA (1) CA2914026A1 (pt)
WO (1) WO2014197543A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201507894D0 (en) 2015-05-08 2015-06-24 Imagen Biotech Ltd Personalised media
SG11201806609TA (en) 2016-02-02 2018-09-27 Guardant Health Inc Cancer evolution detection and diagnostic
US11932898B2 (en) 2016-07-29 2024-03-19 University Of Miami Precision therapeutic biomarker screening for cancer
WO2018078142A1 (en) 2016-10-28 2018-05-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods for determining efficacy of fluorouracil (5-fu) in colorectal cancer (crc) therapy
JP6749593B2 (ja) * 2017-03-10 2020-09-02 国立大学法人横浜国立大学 モノクローナル抗体の製造方法
CN111235269A (zh) * 2018-11-28 2020-06-05 中国科学院大连化学物理研究所 Plin2及定量检测plin2的试剂的应用和试剂盒
CN111228289A (zh) * 2018-11-28 2020-06-05 中国科学院大连化学物理研究所 Plin2抑制剂的应用和治疗肿瘤药物混合物
AU2020283390A1 (en) 2019-05-28 2021-12-23 Duke University Methods and apparatuses for patient-derived micro-organospheres
CN110623982B (zh) * 2019-09-23 2023-04-25 四川大学华西医院 卵巢表面上皮细胞的3d-emt免疫活性制剂及制备与应用
WO2022147259A1 (en) * 2020-12-31 2022-07-07 Elephas Biosciences Corporation Ex vivo systems and methods for determining the effect of a drug or other agent on a tissue
CN117089621A (zh) * 2023-09-28 2023-11-21 上海爱谱蒂康生物科技有限公司 生物标志物组合及其在预测结直肠癌疗效中的应用
CN117603973B (zh) * 2023-11-22 2024-05-14 青岛大学附属医院 一种靶向抑制Agrin基因的shRNA及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270172A (en) * 1991-04-26 1993-12-14 Dekk-Tek, Inc. Method to predict tumor response to therapy
US20070172844A1 (en) * 2005-09-28 2007-07-26 University Of South Florida Individualized cancer treatments
CA2700978A1 (en) * 2007-09-28 2009-04-02 Duke University Individualized cancer treatments
WO2012129538A1 (en) * 2011-03-24 2012-09-27 Whitehead Institute For Biomedical Research Compositions and methods for culturing cells from normal human tubo-ovarian epithelium and human tubo-ovarian tumors
EP2766500A4 (en) * 2011-10-14 2015-10-14 Univ Ohio State METHODS AND MATERIALS RELATED TO OVARIAN CANCER

Also Published As

Publication number Publication date
CA2914026A1 (en) 2014-12-11
US20160102365A1 (en) 2016-04-14
AU2014275006A1 (en) 2015-12-24
JP2016523527A (ja) 2016-08-12
WO2014197543A1 (en) 2014-12-11
EP3004394A4 (en) 2016-12-21
EP3004394A1 (en) 2016-04-13

Similar Documents

Publication Publication Date Title
BR112015030287A2 (pt) ensaios, métodos e kits para analisar a sensibilidade e resistência a fármacos anti-câncer, prevendo o prognóstico de um paciente oncológico e estratégias de tratamento personalizadas
BRPI0509979A (pt) método para detectar ncrna
Roth et al. Prognostic Role of ERCC1 in Advanced Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
Chen et al. Metabolomics of gastric cancer metastasis detected by gas chromatography and mass spectrometry
Holdenrieder Biomarkers along the continuum of care in lung cancer
BR112013027124A2 (pt) método e sistema para analisar características de tecido
BR112015000018A2 (pt) método e aparelho para determinar as contagens de células brancas do sangue
BR112013010015A2 (pt) aparelho e método para detecção não invasiva de doenças que afetam as propriedades estruturais em tecidos biológicos
Jenkinson et al. Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cancer
BR112017007962A2 (pt) método implementado por computador, aparelho, mídia de armazenamento, programa de computador, kit, e, uso do kit
BR112012025593A2 (pt) biomarcadores em circulação para doença
BR112017018008A2 (pt) ?métodos de prognóstico e/ou diagnóstico do câncer, para determinação da dosagem de um produto, para adaptar a dosagem de um produto, para determinar os efeitos benéficos e/ou adversos de uma substância, para identificar um paciente como respondedor a um tratamento, para identificar um paciente como não respondedor a um tratamento, para tratar o câncer, meios para prognosticar e/ou diagnosticar, kit, uso dos meios e dispositivo para a identificação de câncer?
BR112017004899A2 (pt) detecção de proteínas mal dobradas
BR112014026648A8 (pt) método implementado por um dispositivo de computação e aparelho para determinar uma porção futura de um programa de mídia
BR112015012616A2 (pt) método para avaliação da presença ou risco de tumores de cólon
BR112015017767A2 (pt) sistema para detectar estágios do sono de um indivíduo, método para detectar estágios do sono de um indivíduo, e, sistema configurado para detectar estágios do sono de um indivíduo
BR112015018213A2 (pt) método para determinar a síndrome da angústia respiratória aguda (ards) relacionada aos biomarcadores, um método para monitorar o desenvolvimento e o tratamento da ards em um paciente
BR112016018044A2 (pt) teste de diagnóstico molecular para prever resposta às drogas antiangiogênicas e prognóstico de câncer
AR103935A1 (es) Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th-2
BR112018071583A2 (pt) métodos para determinar dpp3 e métodos terapêuticos
NZ714049A (en) Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
BR112016007037A2 (pt) método para detectar câncer pancreático, anticorpo monoclonal e kit
Su et al. Prognostic value of nutritional impairment on treatment‐related toxicity and survival in patients with nasopharyngeal carcinoma taking normal nutrition before radiotherapy
BR112015022977A2 (pt) métodos para predição de risco de metástase em melanoma cutâneo
MX2019013953A (es) Metodo basado en expresion genica para clasificar pacientes con cancer de riñon de acuerdo al riesgo de recurrencia.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]